Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Change in Accured Expenses (2016 - 2025)

Creative Medical Technology Holdings has reported Change in Accured Expenses over the past 15 years, most recently at -$39920.0 for Q1 2025.

  • Quarterly Change in Accured Expenses changed N/A to -$39920.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$39920.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$39920.0 for FY2025, N/A changed from the prior year.
  • Change in Accured Expenses was -$39920.0 for Q1 2025 at Creative Medical Technology Holdings, down from -$3000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $35000.0 in Q2 2022 and troughed at -$39920.0 in Q1 2025.
  • The 4-year median for Change in Accured Expenses is $814.0 (2021), against an average of -$340.91.
  • Peak annual rise in Change in Accured Expenses hit 114.34% in 2022, while the deepest fall reached 1328.5% in 2022.
  • Tracing CELZ's Change in Accured Expenses over 4 years: stood at -$5534.0 in 2021, then crashed by 171.05% to -$15000.0 in 2022, then skyrocketed by 80.0% to -$3000.0 in 2024, then tumbled by 1230.67% to -$39920.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$39920.0, -$3000.0, and $3000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.